Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")
Result of AGM
Ondine Biomedical (AIM: OBI) announces that at its Annual General Meeting held on 24 May 2023 all resolutions were duly passed.
Ondine Biomedical Inc. |
|
Angelika Vance, Corporate Communications |
+001 (1) 604 838 2702 |
|
|
Singer Capital Markets (Nominated Adviser and Joint Broker) |
|
Aubrey Powell, Asha Chotai, Sam Butcher |
+44 (0)20 7496 3000 |
|
|
RBC Capital Markets (Joint Broker) |
|
Rupert Walford, Kathryn Deegan |
+44 (0) 20 7653 4000 |
|
|
Vane Percy & Roberts (Media Contact) |
|
Simon Vane Percy, Amanda Bernard |
+44 (0) 77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave™. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.